Genenta Science S.P.A. - Understand $gnta stock

$GNTA Market Cap: $96.02 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$22.05M

TTM

Current Assets

$18.57M

Q2 2024

Current Liabilities

$1.996M

Q2 2024

Current Ratio

930.42%

Q2 2024

Total Assets

$19.02M

Q2 2024

Total Liabilities

$2.200M

Q2 2024

Book Value

$16.82M

Q2 2024

Cash

$2.243M

Q2 2024

P/E

-4.355

Nov 29, 2024 EST

Free Cash Flow

-$18.16M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019
Selling, General & Admin	$5.259M	$5.705M	$2.297M	$901.8K	$921.5K
YoY Change	-7.83%	148.41%	154.68%	-2.14%
% of Gross Profit
Research & Development	$6.474M	$5.339M	$3.391M	$4.688M	$3.703M
YoY Change	21.27%	57.46%	-27.68%	26.61%
% of Gross Profit
Depreciation & Amortization	$42.45K	$6.140K	$4.890K	$1.900K	$0.00
YoY Change	591.37%	25.56%	157.37%
% of Gross Profit
Operating Expenses	$11.73M	$11.04M	$5.687M	$5.590M	$4.625M
YoY Change	6.24%	94.19%	1.74%	20.88%
Operating Profit	-$11.73M	-$11.04M	-$5.687M	-$5.590M
YoY Change	6.24%	94.19%	1.74%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019
Interest Expense	$92.36K	$36.99K	-$11.72K	-$7.750K	-$9.550K
YoY Change	149.69%	-415.61%	51.23%	-18.85%
% of Operating Profit
Other Income/Expense, Net	-$4.880K	$2.566M	$169.7K	$5.970K	$36.33K
YoY Change	-100.19%	1412.57%	2741.88%	-83.57%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019
Pretax Income	-$11.65M	-$8.478M	-$5.529M	-$5.592M	-$4.598M
YoY Change	37.36%	53.32%	-1.12%	21.63%
Income Tax	$0.00		$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.65M	-$8.500M	-$5.529M	-$5.592M	-$4.598M
YoY Change	37.01%	53.73%	-1.12%	21.63%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.64	-$0.47	-$0.37
Diluted Earnings Per Share	-$0.64	-$0.47	-$303.5K	-$308.6K	-$253.7K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019
Cash & Short-Term Investments	$18.78M	$29.79M	$37.24M	$15.47M	$20.14M
YoY Change	-36.98%	-19.99%	140.8%	-23.22%
Cash & Equivalents	$4.020K	$4.020K	$4.070K	$2.440K	$4.350K
Short-Term Investments	$15.08M
Other Short-Term Assets	$442.8K	$322.9K	$40.24K	$308.3K	$28.53K
YoY Change	37.12%	702.53%	-86.95%	980.62%
Inventory
Prepaid Expenses
Receivables	$34.11K	$41.15K	$58.01K		$0.00
Other Receivables	$2.004M	$1.562M	$1.421M		$429.6K
Total Short-Term Assets	$21.26M	$31.72M	$38.76M	$16.53M	$20.60M
YoY Change	-32.99%	-18.16%	134.42%	-19.74%
Property, Plant & Equipment	$82.98K	$111.6K	$23.09K	$18.97K	$0.00
YoY Change	-25.67%	383.5%	21.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$210.6K	$42.43K	$3.350K	$3.350K	$0.00
YoY Change	396.28%	1166.57%	0.0%
Total Long-Term Assets	$1.091M	$1.716M	$1.268M	$967.9K	$748.7K
YoY Change	-36.45%	35.41%	30.96%	29.29%
Total Assets	$22.35M	$33.44M	$40.03M	$17.50M	$21.35M
YoY Change
Accounts Payable	$295.0K	$1.042M	$164.8K	$545.0K	$279.7K
YoY Change	-71.69%	532.24%	-69.76%	94.85%
Accrued Expenses	$1.015M	$691.6K	$844.5K	$1.725M	$1.866M
YoY Change	46.72%	-18.1%	-51.05%	-7.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.736M	$2.184M	$1.135M	$2.333M	$2.486M
YoY Change	-20.51%	92.37%	-51.36%	-6.14%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$179.3K	$116.2K	$30.62K	$17.39K	$11.33K
YoY Change	54.29%	279.43%	76.08%	53.49%
Total Long-Term Liabilities	$179.3K	$116.2K	$30.62K	$17.39K	$11.33K
YoY Change	54.29%	279.43%	76.08%	53.49%
Total Liabilities	$1.915M	$2.300M	$1.166M	$2.351M	$2.497M
YoY Change	-16.73%	97.29%	-50.41%	-5.87%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	18.22M shares	18.22M shares	15.08M shares
Diluted Shares Outstanding	18.22M shares	18.22M shares	15.08M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $96.022 Million

About Genenta Science S.p.A.

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 14 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.

Industry: Biological Products, (No Diagnostic Substances) Peers: